Last updated on December 2018

A Single-dose Study in Paediatric Subjects Aged 2 to Less Than 18 Years With (sHPT) Receiving Haemodialysis

Brief description of study

This is a multicenter, open-label study to evaluate the safety and pharmacokinetics in pediatric subjects with secondary hyperparathyroidism receiving a single dose of AMG 416 at the end of hemodialysis.

Detailed Study Description

A Single-dose Study to Evaluate the Safety and Pharmacokinetics in Paediatric Subjects Aged 2 to less than 18 Years with (sHPT) Receiving Maintenance Haemodialysis

Clinical Study Identifier: NCT02833857

Contact Investigators or Research Sites near you

Start Over

Amgen Call Center

Research Site
Bruxelles, Belgium

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.